Skandanana Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 27-10-2024
- Paid Up Capital ₹ 0.10 M
as on 27-10-2024
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.99 Cr
as on 27-10-2024
- Revenue 6.87%
(FY 2023)
- Profit -242.93%
(FY 2023)
- Ebitda -198.83%
(FY 2023)
- Net Worth -119.22%
(FY 2023)
- Total Assets 90.32%
(FY 2023)
About Skandanana Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.99 Cr.
Nagendra Vallamkonda and Vallamkonda Sravani serve as directors at the Company.
- CIN/LLPIN
U93000TG2020PTC140032
- Company No.
140032
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Apr 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Skandanana Pharma Private Limited offer?
Skandanana Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Skin Lightening Drugs, Pain Relief Drugs & Pharmaceuticals, Anesthetic, Antihistamines, Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Anti Infective Agent, Antibiotic Injection, Cardiovascular Drugs & Medication.
Who are the key members and board of directors at Skandanana Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagendra Vallamkonda  | Director | 01-Apr-2020 | Current |
| Vallamkonda Sravani | Director | 01-Apr-2020 | Current |
Financial Performance of Skandanana Pharma.
Skandanana Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.87% increase. The company also saw a substantial fall in profitability, with a 242.93% decrease in profit. The company's net worth observed a substantial decline by a decrease of 119.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skandanana Pharma?
Unlock access to Skandanana Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Sansec Pharma Solutions Private LimitedActive 6 years 9 monthsNagendra Vallamkonda is a mutual person
- Skandanan Infra Projects Private LimitedActive 2 years 5 months
Nagendra Vallamkonda and Vallamkonda Sravani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Jan 2023 | ₹1.99 Cr | Open |
How Many Employees Work at Skandanana Pharma?
Unlock and access historical data on people associated with Skandanana Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skandanana Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skandanana Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
